JP Morgan Cazenove announced Shire PLC (LON:SHP), maintaining its target price at 6,300.00GBX today
- Updated: September 18, 2016
Boasting a price of 5,145.00GBX, Shire PLC (LON:SHP) traded 3.22% higher on the day. The last stock price close is up 15.37% from the two hundred day moving average, compared with the S&P 500 which has fallen -0.01% over the same period. The company has been tracking to a 50-day average of 4,943.59GBX and two hundred day average of 4,416.34GBX. 4,917,584 shares of Shire PLC traded hands, up from ann average volume of 2,157,220
Indicating a possible upside of 0.22%, JP Morgan Cazenove held the price target of Shire PLC (LON:SHP) at 6,300GBX
Recent Performance Chart:
Also covering Shire PLC’s stock price target, a total of 18 firms have issued a research note on the stock. The one year target stock price is 73.73GBX with six analysts rating the company a strong buy, 16 analysts rating the company a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 brokerages rating the company as sell.
Shire PLC has a P/E of 32 with a one-year low of 2,707.19GBX and a 52 week high of 5,562.83GBX. The company’s market capitalization is currently 0.0 GBX.
About Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), and GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.